At 12 months, patients who transitioned to generic lost an average of 18.3% of their body weight from baseline.
Patients had a mean baseline BMI of 36.4 kg/m.
After transitioning to generic antiobesity medications, patients maintained a mean BMI of 27.9 kg/m at 12 and 18 months.
Further follow-up indicated a total average weight loss of 25.5% compared to the initial visit.
The findings suggest that older-generation antiobesity medications may effectively support weight maintenance after initial weight loss with .
Simplified
OBJECTIVE: The high cost of novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) class agents often limits access and creates barriers to care. This real-world study evaluated the efficacy of older-generation generic (AOMs) for weight maintenance after 1 year of GLP-1 RA therapy in patients who had achieved successful weight loss.
METHODS: We prospectively followed patients (N = 105) who had completed 12 months of therapy and were part of a "medical weight loss bundle," which included 12 months of GLP-1 RA therapy followed by 6 months of transition care. The baseline mean BMI was 36.4 kg/m. Body weight outcomes were measured at 6, 12, 18, and 24 months. 2
RESULTS: After the medical weight loss bundle, 40 patients transitioned to generic AOMs. At 12 months, this cohort lost an average of 18.3%, 95% CI [13.0%, 23.6%] body weight from baseline, with a mean BMI of 27.9 kg/m. At 18 months, they maintained the weight loss, with a mean BMI of 27.9 kg/m. Subsequent follow-up visits (average 1.5 months later) without GLP-1 RAs showed further reduction, resulting in a total average weight loss of 25.5%, 95% CI [23.1%, 27.9%] compared to the initial visit. 2 2
CONCLUSIONS: Patients successfully treated with GLP-1 RAs can maintain their weight loss using generic older-generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.
Key numbers
18.3%
Average Weight Loss at 12 Months
Percentage weight loss from baseline after 12 months on .
25.5%
Total Average Weight Loss
Percentage weight loss compared to initial visit after 18 months.
27.9 kg/m²
Mean BMI at 18 Months
Mean body mass index of patients at 18 months post-transition.
Full Text
We can’t show the full text here under this license.
Gitanjali Srivastava reports receiving advisory fees from Novo Nordisk, Eli Lilly and Company, and Rhythm Pharmaceuticals; being on the speaker's bureau for Novo Nordisk and Eli Lilly; and receiving research grant support from Eli Lilly and Company. The other authors declared no conflict of interest.
